682 related articles for article (PubMed ID: 14711314)
1. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.
Arttamangkul S; Ishmael JE; Murray TF; Grandy DK; DeLander GE; Kieffer BL; Aldrich JV
J Med Chem; 1997 Apr; 40(8):1211-8. PubMed ID: 9111295
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
Bennett MA; Murray TF; Aldrich JV
J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
[TBL] [Abstract][Full Text] [Related]
4. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
Vig BS; Zheng MQ; Murray TF; Aldrich JV
J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
[TBL] [Abstract][Full Text] [Related]
5. A novel N-terminal cyclic dynorphin A analogue cyclo(N,5)[Trp(3),Trp(4),Glu(5)] dynorphin A-(1-11)NH(2) that lacks the basic N-terminus.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2003 Apr; 46(8):1279-82. PubMed ID: 12672226
[TBL] [Abstract][Full Text] [Related]
6. [Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist.
Patkar KA; Yan X; Murray TF; Aldrich JV
J Med Chem; 2005 Jul; 48(14):4500-3. PubMed ID: 15999987
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2.
Lung FD; Collins N; Stropova D; Davis P; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Mar; 39(5):1136-41. PubMed ID: 8676350
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution.
Choi H; Murray TF; DeLander GE; Schmidt WK; Aldrich JV
J Med Chem; 1997 Aug; 40(17):2733-9. PubMed ID: 9276018
[TBL] [Abstract][Full Text] [Related]
9. Dynorphin A analogs containing a conformationally constrained phenylalanine derivative in position 4: reversal of preferred stereochemistry for opioid receptor affinity and discrimination of kappa vs. delta receptors.
Aldrich JV; Zheng QI; Murray TF
Chirality; 2001; 13(3):125-9. PubMed ID: 11270320
[TBL] [Abstract][Full Text] [Related]
10. Development of highly potent and selective dynorphin A analogues as new medicines.
Lung FD; Chen CH; Liu JH
J Pept Res; 2005 Nov; 66(5):263-76. PubMed ID: 16218994
[TBL] [Abstract][Full Text] [Related]
11. The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
Patkar KA; Murray TF; Aldrich JV
J Med Chem; 2009 Nov; 52(21):6814-21. PubMed ID: 19807094
[TBL] [Abstract][Full Text] [Related]
12. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties.
Schmidt R; Wilkes BC; Chung NN; Lemieux C; Schiller PW
Int J Pept Protein Res; 1996 Nov; 48(5):411-9. PubMed ID: 8956074
[TBL] [Abstract][Full Text] [Related]
13. Effects of modifications of residues in position 3 of dynorphin A(1-11)-NH2 on kappa receptor selectivity and potency.
Lung FD; Meyer JP; Lou BS; Xiang L; Li G; Davis P; DeLeon IA; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Jun; 39(13):2456-60. PubMed ID: 8691442
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of dynorphin a analogues modified in the address sequence.
Schlechtingen G; DeHaven RN; Daubert JD; Cassel JA; Chung NN; Schiller PW; Taulane JP; Goodman M
J Med Chem; 2003 May; 46(11):2104-9. PubMed ID: 12747782
[TBL] [Abstract][Full Text] [Related]
15. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245
[TBL] [Abstract][Full Text] [Related]
16. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.
Przydzial MJ; Pogozheva ID; Bosse KE; Andrews SM; Tharp TA; Traynor JR; Mosberg HI
J Pept Res; 2005 Mar; 65(3):333-42. PubMed ID: 15787963
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel basic head-to-side-chain cyclic dynorphin A analogs: strategies and side reactions.
Vig BS; Murray TF; Aldrich JV
Biopolymers; 2003; 71(6):620-37. PubMed ID: 14991673
[TBL] [Abstract][Full Text] [Related]
18. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 1. Conformational constraint in the "message" sequence.
Arttamangkul S; Murray TF; DeLander GE; Aldrich JV
J Med Chem; 1995 Jun; 38(13):2410-7. PubMed ID: 7608905
[TBL] [Abstract][Full Text] [Related]
20. Design of novel bicyclic analogues derived from a potent oxytocin antagonist.
Flouret G; Chaloin O; Borovickova L; Slaninová J
J Pept Sci; 2006 Jun; 12(6):412-9. PubMed ID: 16432806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]